Eli Lilly’s Retatrutide Phase III Data Sets a New Benchmark in Weight Loss; Pipeline Strength Viewed Favorably

Overview

This report summarizes key insights from the 2026 American Diabetes Association (ADA) Scientific Sessions and Key Opinion Leader (KOL) meetings, focusing on the latest clinical data from Eli Lilly (LLY), Pfizer (PFE), and Structure Therapeutics (GPCR) in the diabetes and obesity (Diabesity) space. The central conclusion is that Eli Lilly’s triple agonist Retatrutide has demonstrated unprecedented weight loss, setting a new industry benchmark and solidifying its leadership position in the competitive landscape. Pfizer’s Berobenatide, while competitive, faces scrutiny over tolerability during the transition from weekly to monthly dosing. Structure Therapeutics’ oral GLP-1 drug Aleniglipron shows promising Phase II results and is progressing smoothly. The firm believes the $190 billion market can accommodate multiple players, with different therapies likely to find niches across diverse patient populations.

Core views

Eli Lilly (LLY): Retatrutide sets a new efficacy standard. Eli Lilly presented complete Phase III data for Retatrutide (a GLP-1/GIP/glucagon triple agonist) from the TRIUMPH-1 (obesity) and TRANSCEND-T2D-1 (type 2 diabetes) trials. In TRIUMPH-1, the 12 mg dose group achieved 28.3% weight loss at Week 80 (vs. 2.2% in the placebo group), with gains reaching 30.3% in the high-BMI subgroup. These results significantly outperform existing options like Zepbound (~23%) and semaglutide. KOLs view this as the best weight loss outcome reported to date, opening new possibilities. Safety remains manageable, though nausea rates are moderate, vomiting rates are elevated, and rare sensory disturbances and urinary tract infections (UTIs) have been observed—most cases being mild to moderate. Eli Lilly plans to file for obesity approval in H2 2026, with a 2027 launch. Additionally, its oral small-molecule GLP-1 drug Foundayo has received positive feedback after two months on the market, and the selective amylin receptor agonist Eloralintide is advancing, expected to launch in 2028. Pfizer (PFE): Berobenatide’s tolerability under scrutiny, with a focus on monthly dosing. Pfizer shared full Phase II data for Berobenatide (an injectable GLP-1). While efficacy is competitive, discussions centered on tolerability, particularly the spike in vomiting rates (up to 24%) when transitioning from weekly to monthly dosing. KOLs remain cautious, emphasizing the need for additional data. Pfizer has adjusted the Phase III titration regimen to improve tolerability and aims to launch the weekly formulation in 2028, followed by rapid approval of the monthly version. The firm views Berobenatide more as a competitor to Amgen’s Maritide than as a direct challenge to Eli Lilly’s flagship product. Structure Therapeutics (GPCR): Oral GLP-1 data is encouraging. GPCR released complete Phase II results for Aleniglipron (an oral GLP-1), showing dose-dependent weight loss without increased adverse events or liver toxicity at higher doses. Re-dosing after interruptions did not trigger recurrent vomiting, addressing a major hurdle for oral GLP-1 agents. The company plans to initiate Phase III in Q3 2026. Furthermore, its oral amylin/DACRA combination drug ACCG-2671 has preclinical data suggesting potential comparable to Novo Nordisk’s Cagri+Sema.

Analysis framework

The firm employed a combined approach of cross-trial comparison and KOL expert interviews. First, it assessed relative competitive advantages by comparing key efficacy metrics (e.g., percent weight loss, HbA1c reduction) and safety indicators (e.g., discontinuation rates due to adverse events, incidence of specific side effects) across companies. Second, it incorporated perspectives from academic endocrinologists to interpret how these data might reshape treatment paradigms from a real-world clinical standpoint—considering prescribing habits, payer constraints, and side-effect management—to gauge market penetration potential and commercial prospects. Finally, it integrated each company’s R&D pipeline and commercialization strategy to inform valuation and rating maintenance decisions.

Methodology notes

• Industry/Industrial Analysis FrameworkSupply-demand framework

  Cross-trial Comparison

  In the absence of head-to-head trials, the firm infers relative market positioning by comparing efficacy and safety data across different drugs within their respective clinical trials, accounting for baseline differences and other limitations. This is a common method for evaluating competitive strength in the biopharmaceutical sector.

• Event Game Theory and Behavioral FinanceExpectation Gap/Expectations Management

  KOL Perspective Validation

  The firm conducts interviews with Key Opinion Leaders (KOLs) to capture clinicians’ genuine reactions to the latest data and their prescribing intentions, thereby calibrating market expectations regarding a drug’s commercial potential. KOL feedback often reveals practical barriers or opportunities hidden behind the data.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• Eli Lilly & Co. (LLY.N)

  Beneficiary: Retatrutide data establishes a new industry benchmark; robust pipeline; strong commercial momentum.

  Strengths

  Broadest diabetes/obesity pipeline; exceptional Retatrutide efficacy; oral small-molecule GLP-1 unburdened by peptide constraints.

  Weaknesses

  Specific risks of vomiting, sensory disturbances, and UTIs with Retatrutide.

  Comparison

  Compared to Novo Nordisk, Eli Lilly offers differentiation in triple agonists and oral small molecules.

  Risks

  Competitor data exceeding expectations; underperformance of Foundayo or Elora/Reta in clinical or commercial execution.

• Pfizer Inc (PFE.N)

  Neutral/Slightly Beneficial: Berobenatide data supports advancement to Phase III, but tolerability concerns may weigh on market sentiment.

  Strengths

  Potential convenience of monthly dosing; proven track record of successfully penetrating primary care markets.

  Weaknesses

  Prominent tolerability challenges (vomiting) when shifting from weekly to monthly dosing; R&D lagging behind leaders.

  Comparison

  More positioned as a competitor to Amgen’s Maritide than as a direct threat to Eli Lilly’s core offerings.

  Risks

  Existing franchises face commercial challenges; pipeline setbacks; decline in COVID-related revenues.

• Structure Therapeutics Inc (GPCR.O)

  Beneficiary: Positive oral GLP-1 data; clear development path; potential for differentiation.

  Strengths

  Convenience of oral administration; favorable tolerability and safety profile (no liver toxicity); combination therapy potential.

  Weaknesses

  Limited resources as a smaller biotech facing competition from larger pharmaceutical firms.

  Comparison

  Competing in the oral space with Eli Lilly’s Foundayo and Novo Nordisk’s Oral Wegovy, yet delivering competitive data.

  Risks

  Disappointing GSBR-1290 data (referring here to Aleniglipron’s core oral pipeline); development delays.

Key data

• Retatrutide Weight Loss Efficacy28.3% (Week 80, 12 mg)TRIUMPH-1 trial; 30.3% in the high-BMI subgroup
• Retatrutide HbA1c Reduction~2.0%TRANSCEND-T2D-1 trial, Week 40
• Berobenatide Monthly Dosing Vomiting Rate24%Peak observed upon switching from weekly to monthly dosing
• Aleniglipron Weight Loss Efficacy16.3% (Week 44, 180 mg)ACCESS II trial, following placebo adjustment
• Eli Lilly’s Incretin Franchise Sales Forecast$100 billion (2035E)Up from ~$60 billion in 2026

Impact & implications

The report concludes that Eli Lilly, bolstered by Retatrutide’s outstanding data and its broad pipeline—including oral small molecules and amylin agonists—has further strengthened its competitive edge in the diabetes and obesity markets and is poised to become a dominant force. Pfizer, though entering later, could still carve out a niche if it resolves tolerability issues with its differentiated monthly dosing strategy, particularly among patients sensitive to injection frequency. Structure Therapeutics’ oral GLP-1, if it replicates Phase II results in Phase III, stands to become a significant player, especially among patients who prefer oral medications or have reservations about injections. Overall, the $190 billion market is large enough to support coexistence among multiple mechanisms and delivery formats, but competition will intensify, with the balance between efficacy and tolerability proving decisive.

Risks

• Serious, unexpected safety issues arise with candidate drugs such as Retatrutide or Berobenatide.
• Clinical trial outcomes fall short of expectations or regulatory approvals are delayed.
• Intensified market competition leads to pricing pressure or loss of market share.
• Payers impose restrictive reimbursement policies for novel, high-cost weight-loss drugs.

What to watch

• Follow-up data from Eli Lilly’s RETRIUMPH-2 and RETRIUMPH-3 trials.
• Detailed Phase III tolerability data for Pfizer’s Berobenatide in its monthly dosing regimen.
• Progress in initiating and early results from Structure Therapeutics’ Aleniglipron Phase III trial.
• Early commercial feedback and market acceptance of each company’s oral GLP-1 products.